瑞舒伐他汀调脂外作用对炎症因子的影响研究

Effects of Rosuvastatin on Inflammatory Factors besides Lipid-regulating Effect

目的:比较瑞舒伐他汀和阿托伐他汀调脂外作用对炎症因子的影响。方法:前瞻性随机将127例患者分为阿托伐他汀组(63例)和瑞舒伐他汀组(64例),检测治疗前和治疗3周后血清超敏C反应蛋白(hsCRP)、纤维蛋白原(Fig)、纤溶酶原激活剂抑制因子1(PAI-1)等炎症因子以及总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、甘油三酯(TG)等血脂水平,并分析炎症因子变化与血脂水平的相关性。结果:2组治疗3周后与治疗前血脂指标(TG除外)、炎症因子各指标比较差异均有统计学意义(P<0.05),且瑞舒伐他汀组降低TC、LDL-C水平,升高HDL-C水平以及降低血清hsCRP、Fig、PAI-1水平的效果优于阿托伐他汀组(P<0.05);2组血清炎症因子变化与血脂水平无相关性。结论:瑞舒伐他汀较阿托伐他汀更能显著降低患者血清hsCRP、Fig和PAI-1水平,且抗炎作用是独立于调脂作用之外。

OBJECTIVE： To compare the effects of rosuvastatin vs. atorvastatin on inflammatory factors besides lipid-regulating effect. METHODS： In prospective randomized trials, 127 patients were divided into atorvastatin group （63 cases） and rosuvastatin group （64 cases）. The correlation of serum high sensitivity C-reactive protein （hsCRP）, fibrinogen （Fig） and plasminogen activator inhibitor 1 （PAI-1） levels with the changes of total cholesterol （TC）, low-density lipoprotein cholesterol （LDL-C）, high density lipoprotein cholesterol （HDL-C） and triglycerides （TG） were detected before treatment and after three weeks of treatment. RESULTS： There was statistical significance in lipid parameters （except for TG） and the inflammatory factors between 2 groups after 3 weeks of treatment （P0.05）. The decrease range of TC, LDL-C levels, serum hsCRP, Fig and PAI-1 and the increase range of HDL-C levels in rosuvastatin group were greater than in atorvastatin group （P0.05）. The change of inflammatory factors had no correlation with the lipid changes in 2 groups. CONCLUSION： Rosuvastatin is more effective than atorvastatin in lowering serum hsCRP, Fig and PAI-1 levels. The anti-inflammatory effect is independent of lipid-regulating effect.